The Use of Cyclosporine in Dermatology

103. DeWitt CA, Bishop AB, Buescher LS, Stone SP. Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J Am Acad Dermatol. 2006;54:855-65.
104. Wolach B, Eliakim A, Pomeranz A, Cohen AH, Nusbacher J, Metzker A. Cyclosporin treatment of hyperimmunoglobulin E syndrome. Lancet 1996;347:67
105. Schepis C, Lentini M, Siragusa M. Erosive lichen planus on an atypical site mimicking a factitial dermatitis. Acta Derm Venereol. 2010;90:185-6.
106. Schepis C, Siragusa M, Lentini M. Erosive lichen planus: two uncommon cases Acta Derm Venereol. 2008;88:268-70.
107. Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007 Jun;49(2):89-106. Review. PubMed PMID: 17634721.
108. Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen planopilaris. J Am Acad Dermatol. 2003;49:667-71
109. Lane TK, Kamino H, Walters RF, Meehan S, Pomeranz MK. Lichen planopilaris and psoriasis. Dermatol Online J. 2008;14:4.
110. Bulbul Baskan E, Turan H, Tunali S, Toker SC, Saricaoglu H. Open-label trial of cyclosporine for vulvar lichen sclerosus. J Am Acad Dermatol 2007;57:276-8.
111. Schiavo AL, Puca RV, Ruocco V, Ruocco E. Adjuvant drugs in autoimmune bullous iseases, efficacy versus safety: Facts and controversies. Clin Dermatol. 2010;28:337-43.
112. Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, Blaszczyk M. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8:85-92.
113. Tirado-Sánchez A, León-Dorantes G. Treatment of pemphigus vulgaris. An overview in Mexico. Allergol Immunopathol (Madr). 2006 Jan;34:10-6.
114. Chrysomallis F, Ioannides D, Teknetzis A, Panagiotidou D, Minas A. Treatment of oral pemphigus vulgaris. Int J Dermatol. 1994;33:803-7.
115. Alsaleh QA, Nanda A, Al-Baghli NM, Dvorak R. Pemphigus in Kuwait. Int J Dermatol. 1999;38:351-6.
116. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006263.
117. Millard TP, Hawk JL. Photosensitivity disorders: cause, effect and management. Am J Clin Dermatol. 2002;3:239-46.
118. Stinco G, Codutti R, Frattasio A, De Francesco V, Patrone P. Chronic actinic dermatitis treated with cyclosporine-A. Eur J Dermatol. 2002;12:455-7.
119. Booth AV, Ma L. Pityriasis rubra pilaris, type 1. Dermatol Online J. 2005;11:9.
120. Usuki K, Sekiyama M, Shimada T, Shimada S, Kanzaki T. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology. 2000;200:324-7.
121. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-78.
122. Ippoliti G, Miori L, Negri M, Rovati B, Lorenzutti F, Zerbinati N, Rabbiosi G. Cyclosporine in treatment of progressive systemic sclerosis: clinical and immunologic findings. Transplant Proc. 1994;26:3117-8.
123. Morton SJ, Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford). 2000;39:865-9.
124. Worswick S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther. 2011;24:207-18.
125. Kumari R, Timshina DK, Thappa DM. Drug hypersensitivity syndrome. Indian J Dermatol Venereol Leprol. 2011;77:7-15.
126. Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F, Lim R, Papini R, Moiemen N, Lewis H. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. Clin Exp Dermatol. 2010;35:853-62.
127. Paquet P, Piérard GE. New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Saf. 2010;33:189-212.
128. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens- Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97:272-80.
129. Matsushita K, Ozaki A, Inoue H, Kaieda T, Akimoto M, Satomura A, Arima N, Hamada H, Suruga Y, Aoki N, Fujiwara H, Tei C. Stevens-Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus. Mod Rheumatol. 2006;16:113-6.
130. Peru H, Soylemezoglu O, Bakkaloglu SA, Elmas S, Bozkaya D, Elmaci AM, Kara F, Buyan N, Hasanoglu E. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol. 2008;27:1087-92.
131. Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol. 2006;24:414-29.
132. Venzor J, Lee WL, Huston DP. Urticarial vasculitis. Clin Rev Allergy Immunol. 2002;23:201-16.
133. Tsutsui K, Hirone T, Kubo K, Matsui Y. Annular elastolytic giant cell granuloma: response to cyclosporin A. J Dermatol. 1994;21:426-9.
134. Hayashi M, Kawaguchi M, Mitsuhashi Y, Suzuki T. Case of hypereosinophilic syndrome with cutaneous necrotizing vasculitis. J Dermatol. 2008;35:229-33.
135. Shenoy VV, Joshi SR, Kotwal VS, Shedge RT, Ramraje NN, Lanjewar DN. Recurrent Kimura's disease: excellent response to cyclosporine. J Assoc Physicians India. 2006;54:153-5.
136. Birol A, Bozdogan O, Keles H, Kazkayasi M, Bagci Y, Kara S, Koçak M, Birol A. Kimura's disease in a Caucasian male treated with cyclosporine. Int J Dermatol. 2005;44:1059-60.
137. Sugita K, Kabashima K, Koga C, Tokura Y. Eosinophilic pustular folliculitis successfully treated with sequential therapy of interferon-gamma and ciclosporin. Clin Exp Dermatol. 2006 Sep;31:709-10.
138. Palamaras I, El-Jabbour J, Pietropaolo N, Thomson P, Mann S, Robles W, Stevens HP. Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol. 2008;22:1033-43.
139. Carranza DC, Young L. Successful treatment of metastatic Crohn's disease with cyclosporine. J Drugs Dermatol. 2008;7:789-91.
140. Stanway A, Rademaker M, Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporin. Australas J Dermatol. 2004;45:119-22.
141. Migliore A, Bizzi E, Santacroce CM, Tarquini E, Massafra U, Vacca F, Martin Martin LS. Mixed panniculitis responding to cyclosporin-A with a 12-month follow-up: a case report. Int J Immunopathol Pharmacol. 2009;22:1143-6.
142. Rojnuckarin P, Nakorn TN, Assanasen T, Wannakrairot P, Intragumtornchai T. Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2007;48:560-3.
143. Al Zolibani AA, Al Robaee AA, Qureshi MG, Al Nosian H. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A. Skinmed. 2006;5:195-7.
144. Tajima M, Mitsuhashi Y, Irisawa R, Amagai M, Hashimoto T, Tsuboi R. IgA pemphigus reacting exclusively to desmoglein 3. Eur J Dermatol. 2010;20:626-9. Erratum in: Eur J Dermatol. 2011;21:152.
145. Gergely L, Váróczy L, Vadász G, Remenyik E, Illés A. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol. 2003;109:202-5.
146. Valdés E, Núñez T, Pedraza D, Muñoz H. Recurrent Impetigo Herpetiformis: successfully managed with ciclosporine. Report of one case. Rev Med Chil. 2005;133:1070-4.
147. Bata-Csorgo Z, Husz S, Foldes M, Korom I, Molnar K, Morvay M, Dobozy A. Scleromyxedema. J Am Acad Dermatol. 1999;41(2 Pt 2):343-6.
148. Saigoh S, Tashiro A, Fujita S, Matsui M, Shibata S, Takeshita H, Duan H, Moroi Y, Urabe K, Koga T, Furue M. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology. 2003;207:410-1.
149. Nakajima K, Ikeda M, Nakajima H, Kodama H. Regression of secondary plane xanthomas using cyclosporine A. Int J Dermatol. 2006;45:1136-8.

Address for Correspondence